|
PRIME
CANCER
|
Aaa13-002 | New dual drugs eliminate tumors when combined with immunotherapy |
| Quote: | Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be master regulators of cancer progression. The study, to be published April 2 in the Journal of Experimental Medicine JEM, shows that these drugs, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice, suggesting that they could eventually be used to treat a broad range of cancers in humans.
|
| Article:
| https://www.news-medical.net/news/20260402/New-dual-drugs-eliminate-tumors-when-combined-with-immunotherapy.aspx |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho
|
|
PRIME
BRAIN
CANCER
NUTRITION
|
Aaa13-005 | Aggressive brain cancer may respond to high-dose vitamin therapy, study suggests Majority of glioblastoma patients showed no disease progression after 6 months on vitamin B3 |
| Quote: | Niacin was found to restore function in weakened immune cells, improving their ability to target and destroy tumor cells. ... previous research has shown that vitamin B3 decreases inflammation and bolsters immune function.
|
| Article:
| https://www.foxnews.com/health/aggressive-brain-cancer-may-respond-high-dose-vitamin-therapy-study-suggests |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho
|
|
CANCER
GENETICS
|
Mca13-022 | Cancer-Type Specific Prognostic Impact of Concurrent TP53 and KRAS Alterations: A Multi-Cohort Genomic Analysis |
| Quote: | Patients harboring concurrent TP53 and KRAS alterations exhibited significantly shorter overall survival in pancreatic cancer, colorectal cancer, and ampullary carcinoma, but surprisingly demonstrated the longest survival in gastric cancer. ... The prognostic significance of TP53 and KRAS alterations is profoundly cancer-type specific, driven by differences in mutation subtype distribution, copy number alteration patterns, co-occurring genetic events, and the discordance between genotype and functional expression.
|
| Abstract:
| https://www.medrxiv.org/content/10.64898/2026.03.29.26349383v2 |
| Full Text:
| https://www.medrxiv.org/content/10.64898/2026.03.29.26349383v2.full-text |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho |
| Search Authors: |
Guangchao Pan,
|
|
BRAIN
CANCER
IMMUNE
|
Mca13-024 | A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma |
| Quote: | The protein biomarker panels provide a means to risk stratify patients who are at high risk for developing severe CRS and ICANS, to inform on the need for prophylactic interventions and improve patient outcomes.
|
| Abstract:
| https://www.medrxiv.org/content/10.64898/2026.03.29.26349664v1 |
| Full Text:
| https://www.medrxiv.org/content/10.64898/2026.03.29.26349664v1.full-text |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho |
| Search Authors: |
Ehsan Irajizad, Johannes Francois Fahrmann, Hiroyuki Katayama, Paolo Strati, Ranjit Nair, Michael Wang, Dai Chihara, Luis Fayad, Sairah Ahmed, Swaminathan P Iyer, Frederick L Locke, Marco Davila, Christopher Flowers, Elizabeth Shpall, Sattva Neelapu, Samir Hanash, Jason Westin, Michael D Jain, Teny M John, Neeraj Y Saini,
|
| Search Words: |
|
|
CANCER
PRACTICE
|
Mcr13-026 | Covariate adjustment for hierarchical outcomes and the win ratio: how to do it and is it worthwhile? |
| Abstract:
| https://www.medrxiv.org/content/10.64898/2026.03.30.26347966v1 |
| Full Text:
| https://www.medrxiv.org/content/10.64898/2026.03.30.26347966v1.full-text |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho |
| Search Authors: |
Audinga-Dea Hazewinkel, John Gregson, Jonathan W Bartlett, Samvel B Gasparyan, David Wright, Stuart Pocock,
|
|
CANCER
GENETICS
|
Mge13-004 | Whole-Genome Landscape of Breast Cancers from India shows Distinct Clinically Actionable Subtypes |
| Abstract:
| https://www.medrxiv.org/content/10.64898/2026.03.27.26349506v1 |
| Full Text:
| https://www.medrxiv.org/content/10.64898/2026.03.27.26349506v1.full-text |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho |
| Search Authors: |
Divya Khanna, Arnab Ghosh, Priyanka Bhadwal, Ramakanth Chirravuri-Venkata, Leepakshi Dhingra, Subrata Das, Isha Choubey, Ankita Singh, Geeta Jadaun, Hriday Home Chowdhury, Vibha Mattoo, Pooja Dixit, Suryanshi Tiwari, Safeer Khan, Vinit Gupta, Tuneer R. Mallick, Surya Narayan Mishra, Tulasi Nagabandi, Venkata Krishna Vanamamalai, Malini Nemalikanti, Renu Kumari, Diksha Singhal, Laxmi Yadav, Vaishali Pandey, Shailya Verma, Rashmi Gudur, Senthil Kumar, Susanta Roychoudhury, Rohan Chaubal, Sonam Dhamija, Koushik Mondal, Lipi Thukral, Aruna Korlimarla, Rekha V Kumar, Ashutosh Mishra, Bhawna Sirohi, SVS Deo, Samir Bhattacharya, B S Srinath, Juhi Tayal, Anurag Mehta, Shilpak Chatterjee, Sanjeev Khosla, Divya Tej Sowpati, Kumardeep Chaudhary, Karthik Bharadwaj Tallapaka, Sherry Bhalla, Nidhan K. Biswas, Sudeep Gupta, Shantanu Chowdhury,
|
|
AI-CHAT
CANCER
|
Mhe13-002 | Artificial intelligence-driven virtual tumor board enhances precision care in myelodysplastic syndromes |
| Abstract:
| https://www.medrxiv.org/content/10.64898/2026.03.26.26349088v1 |
| Full Text:
| https://www.medrxiv.org/content/10.64898/2026.03.26.26349088v1.full-text |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho |
| Search Authors: |
David M Swoboda, Amy E DeZern, James T England, Sangeetha Venugopal, Thomas Kehoe, Brandon J Aubrey, Marco Gabriele Raddi, Angela Consagra, Jiasheng Wang, Jonathan Andreadakis, Gustavo Rivero, Maximilian Stahl, Amer M. Zeidan, Torsten Haferlach, Andrew M Brunner, Rena Buckstein, Valeria Santini, Matteo Giovanni Della Porta, Mikkael A Sekeres, Aziz Nazha,
|
|
CANCER
|
Mpc13-024 | Screening for prostate cancer using PSA with and without MRI: systematic reviews with meta-analysis |
| Quote: | Findings about adding MRI for those with a positive PSA test were limited and would require additional consideration of costs, infrastructure, expertise, and equity.
|
| Abstract:
| https://www.medrxiv.org/content/10.64898/2026.03.30.26349764v1 |
| Full Text:
| https://www.medrxiv.org/content/10.64898/2026.03.30.26349764v1.full-text |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho |
| Search Authors: |
Jennifer Pillay, Lindsay A Gaudet, Sholeh Rahman, Roland Grad, Guylene Theriault, Philipp Dahm, Keith J Todd, Gail Macartney, Brett Thombs, Sabrina Saba, Lisa Hartling,
|